Jon Robertson

The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction

Pradeep J. Nathan, Jeannette M. Watson, Lund Jesper et al. · The International Journal of Neuropsychopharmacology · 2012 · 101 citations

Behavioral Addiction, Psychopharmacology, Nicotine Abstinence Model +17

A Randomised Trial Evaluating the Effects of the TRPV1 Antagonist SB705498 on Pruritus Induced by Histamine, and Cowhage Challenge in Healthy Volunteers

Rachel A. Gibson, Jon Robertson, Harshna Mistry et al. · PLoS ONE · 2014 · 73 citations · Full text

A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma

Sanjeev Khindri, Anthony Cahn, Malcolm Begg et al. · Journal of Pharmacology and Experimental Therapeutics · 2018 · 36 citations · Full text

A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤2% and >2% blood eosinophils

Joanna Marks-Kończalik, María J. Costa, Jon Robertson et al. · Respiratory Medicine · 2015 · 30 citations · Full text

Month Clinical Trial, Advanced Lung Disease, Moderate-severe Copd Patients +5

Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach

Amir Inamdar, Emilio Merlo‐Pich, Michelle Gee et al. · Journal of Psychopharmacology · 2014 · 29 citations